Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed small cell lung cancer (SCLC)

- Limited-stage disease, defined as SCLC confined to ≥ 1 of the following:

- One hemithorax

- Ipsilateral supraclavicular fossa

- Measurable disease

- No malignant pleural effusion, contralateral hilar disease, or contralateral
supraclavicular disease

- Minimal pleural effusion visible on CT scan of the chest, but not evident on
chest x-ray, allowed

- No completely surgically resected disease

- No CNS disease, including primary brain tumor or brain metastasis

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Absolute granulocyte count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Bilirubin ≤ 1.5 mg/dL

- Creatinine ≤ 1.5 mg/dL

- Urine protein:creatinine ratio ≤ 0.5 OR 24-hour urine protein < 1,000 mg

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for ≥ 6 months after
completion of study treatment

- INR ≤ 1.5 (unless on full-dose anticoagulants)

- No active serious infection

- No serious or nonhealing wound

- No ulcer or bone fracture

- No evidence of bleeding diatheses or coagulopathy

- No hemoptysis

- No known hypersensitivity to Chinese hamster ovary cell products and/or other
recombinant human antibodies

- No clinically significant cardiovascular disease, including any of the following:

- Uncontrolled hypertension

- New York Heart Association class II-IV congestive heart failure

- Serious cardiac arrhythmia requiring medication

- Unstable angina pectoris

- Symptomatic peripheral vascular disease

- Cerebrovascular accident within the past 6 months

- Symptomatic heart disease within the past 6 months

- Myocardial infarction within the past 6 months

- Unstable angina within the past 6 months

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
the past 4 weeks

- No significant traumatic injury within the past 4 weeks

PRIOR CONCURRENT THERAPY:

- At least 4 weeks since prior major surgery or open biopsy

- At least 1 week since prior core biopsy

- No prior chemotherapy or radiotherapy for small cell lung cancer

- No concurrent major surgery

- No concurrent palliative local radiotherapy

- No concurrent intensity-modulated radiotherapy

- Concurrent full-dose anticoagulants (e.g., warfarin) allowed provided all of the
following criteria are met:

- INR ≤ 3

- In-range INR (2-3) on a stable dose of oral anticoagulant or on a stable dose of
low molecular weight heparin

- No active bleeding or pathological condition that carries a high risk of
bleeding (e.g., tumor involving major vessels or known varices)